Nanox generates $3.0 mln in Q2 revenue, grows Nanox.ARC system sales funnel.

• Nanox reports Q2 revenue of $3.0 million, up from $2.7 million in 2024. • Nanox.ARC system sales funnel grows exponentially. • FDA notified of intent to submit TAP2D software module for Nanox.ARC systems. • New customers include several medical imaging center chains across the US.

Nanox (NASDAQ: NNOX), a medical imaging technology company, reported its Q2 2025 financial results, showcasing a 11% year-over-year (YoY) increase in revenue to $3.0 million, up from $2.7 million in Q2 2024. Despite the revenue growth, the company incurred a net loss of $14.7 million, compared to $13.6 million in the prior year period [2].

Key developments include the exponential growth of the Nanox.ARC system sales pipeline, plans to submit the TAP2D software module to the FDA for 510(k) clearance, and a new partnership with Fabrinet for manufacturing support. The company expanded its presence in the U.S. and EU markets, securing new customers including major imaging center chains and making progress in Romania. Nanox is on track to deploy over 100 units worldwide by the end of 2025 [2].

The company's gross loss margin deteriorated to 107% on a GAAP basis and 21% on a non-GAAP basis, indicating increased operational expenses as it scales its operations. Teleradiology services remain the company's revenue backbone, generating $2.7 million with improving gross profit margins of 18% GAAP and 38% non-GAAP. However, imaging system sales and AI solutions are significant loss centers, with gross losses of $1.7 million and $2.0 million respectively [2].

Nanox's cash balance decreased to $62.6 million from $83.5 million at the end of 2024, with negative operating cash flow of $19.6 million for the period. This positions the company with approximately 18 months of runway at current burn rates [2].

Management remains optimistic, highlighting strategic progress in expanding the Nanox.ARC installed base, growing the sales funnel, and preparing to submit the TAP2D software module to the FDA. The company also reports breakthroughs in the European market and engagement with major U.S. imaging center chains, reaffirming its commitment to continuous product enhancement and accelerating commercialization despite financial challenges [2].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX6B61C3:0-eastman-kodak-q2-revenue-down-1/
[2] https://www.stocktitan.net/news/NNOX/nanox-announces-second-quarter-of-2025-financial-results-and-rykvvun91orq.html